Japan To Lower Price Of Eight Drugs From Takeda, Novartis, BMS And Chugai By 12-18 Percent
This article was originally published in PharmAsia News
Executive Summary
As part of an ongoing re-pricing policy for drugs that have seen expanded market share, Japan's Ministry of Health, Labor and Welfare has decided to lower the price on eight drugs effective April 1
You may also be interested in...
Japan Sets New Reimbursement Prices For NHI-qualified Drugs; Cuts Average 5.75 Percent
TOKYO - Japan's Ministry of Health, Labor and Welfare March 5 posted new reimbursement prices of National Health Insurance-qualified drugs, the first such change in two years. The new prices are effective April 1
Japan Sets New Reimbursement Prices For NHI-qualified Drugs; Cuts Average 5.75 Percent
TOKYO - Japan's Ministry of Health, Labor and Welfare March 5 posted new reimbursement prices of National Health Insurance-qualified drugs, the first such change in two years. The new prices are effective April 1
Chugai Sets Record Results In 2009, Lowers Forecasts For 2010
Roche Japanese unit Chugai Pharmaceutical had its best year ever in 2009, posting record revenue and profits thanks largely to Tamiflu (oseltamivir), which saw Japan sales soar nine-fold to ¥76.2 billion ($852.75 million) in response to the Japanese government and local authorities stockpiling flu drugs